Letter to the editor "A phase 1 study of concurrent cabozantinib and cetuXimab in recurrent or metastatic head and neck squamous cell cancer". Tamil Selvan S. Oral Oncol 2024;157:106958.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tamil Selvan S. Letter to the editor "A phase 1 study of concurrent cabozantinib and cetuXimab in recurrent or metastatic head and neck squamous cell cancer". Oral Oncol 2024;157:106958.
PMID: 39059049